Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heart Leaflet Technologies Inc.

This article was originally published in Start Up

Executive Summary

Heart Leaflet Technologies Inc. is developing two percutaneous aortic heart valves that can be used to repair stenosed or calcified valves without the use of open-heart surgery.

You may also be interested in...



In Heart Valves, The End of Watchful Waiting?

Health Research International has just issued a report, "US Opportunities in Heart Valve Disease Management." According to the report, the market for valve replacement and repair products will grow from more than $500 million in 2004 to some $900 million in 2010, with the greatest growth occurring in percutaneous valve products.

In Heart Valves, a Brave, New, Non-Surgical World

In heart valves, the advent of new, less invasive procedures promises the usual advantages over open surgery and more; lower cost, reduced procedural morbidity, faster healing times, and also, a new kind of intermediate treatment option that could serve new patient groups. Most companies are still in development; two companies have begun clinical trials in a handful of patients. But despite the early stage of the field, it's incited a great deal of controversy, particularly afer heart surgery company Edwards Lifesciences acquired the leading percutaneous valve company for what many view as a surprisingly large chunk of money. Central to the debate is the continuing (and uncertain) role of cardiovascular surgeons, the heart valve experts, once the referring cardiologists get their hands on their own procedure.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel